Geranylgeranyl diphosphate synthase (GGDPS), an enzyme in the isoprenoid biosynthesis
pathway, is responsible for the production of geranylgeranyl pyrophosphate (GGPP). GGPP …

Pulmonary hypertension (PH) is a potentially fatal condition with a prevalence of around 1%
in the world population and most commonly caused by left heart disease (PH-LHD). Usually …

Background: The mevalonate pathway generates endogenous cholesterol and
intermediates including geranylgeranyl pyrophosphate (GGPP). By reducing GGPP …

Pulmonary hypertension due to left heart disease (PH‐LHD) is regarded as the most
prevalent form of pulmonary hypertension (PH). Indeed, PH is an independent risk factor …

Atorvastatin (ATO) is of the statin class and is used as an orally administered lipid-lowering
drug. ATO is a reversible synthetic competitive inhibitor of 3-hydroxy-3-methyl-glutaryl-CoA …

Introduction: Group 2 pulmonary hypertension (PH), defined as a mean pulmonary arterial
pressure≥ 25 mmHg with elevated pulmonary capillary wedge pressure> 15 mmHg, has no …

Pulmonary hypertension due to left heart disease (PH-LHD) is a momentous pulmonary
hypertension disease, and left heart disease is the most familiar cause. Mechanical …

Traditional anti-arrhythmic drugs are classified by the Vaughan-Williams classification
scheme based on their mechanisms of action, which includes effects on receptors and/or ion …

The transcriptional co-activator Yes-associated protein (YAP) functions as a downstream
effector of the Hippo signaling pathway and plays a crucial role in cardiomyocyte survival. In …

Introduction Group 2 pulmonary hypertension (PH) has no approved PH‐targeted therapy.
Metabolic remodelling, specifically a biventricular increase in pyruvate kinase muscle (PKM) …